Skip to content
Clinical Trials – home

Ziekenhuis Gelderse Vallei Stichting

Research site

The Netherlands Willy Brandtlaan 10, 6716 RP Ede, The Netherlands

  • 23 trials recruiting
  • Chronic lymphocytic leukaemia · Non-small cell lung cancer · Arteriosclerosis
  • Adults and children

About Specializations

Ziekenhuis Gelderse Vallei Stichting in Ede, The Netherlands specialises in clinical trials of conditions such as Chronic lymphocytic leukaemia, Non-small cell lung cancer, Arteriosclerosis, Non-small cell lung cancer metastatic, and other specialisations. This site conducts important research.

Main research areas of the site

Oncology

The medical center is at the forefront of oncology research, focusing on innovative therapies for various types of cancer. The center's work in this field is characterized by its commitment to improving patient outcomes through cutting-edge clinical trials and personalized medicine approaches.

  • Non-small cell lung cancer (NSCLC)
  • Follicular and marginal zone lymphoma
  • Advanced solid tumors and non-Hodgkin lymphoma
  • Metastatic colorectal cancer
  • Breast cancer

By integrating targeted therapies and immunotherapy, the center is advancing the treatment landscape for cancer patients, offering hope for improved survival rates and quality of life.

Cardiology

In the realm of cardiology, the center is pioneering research into heart failure and myocardial infarction. The focus is on developing therapies that enhance cardiac function and patient recovery post-heart attack.

  • Myocardial Infarction and Acute Heart Failure
  • ST-Elevation Myocardial Infarction (STEMI)

Through innovative clinical trials, the center is exploring new drug candidates and treatment protocols that aim to reduce mortality and improve long-term cardiac health.

Respiratory Medicine

The center is a leader in respiratory medicine, particularly in the treatment of acute respiratory distress syndrome (ARDS). Research efforts are directed towards finding effective therapies for ARDS caused by pneumonia and other infections.

  • Acute Respiratory Distress Syndrome (ARDS)

By investigating novel therapeutic agents, the center aims to enhance patient survival and recovery, addressing a critical need in respiratory care.

Gastroenterology

In gastroenterology, the center is advancing the understanding and treatment of conditions like Crohn's disease and gastroparesis. The focus is on optimizing therapeutic strategies to improve patient quality of life.

  • Crohn's Disease
  • Idiopathic or Diabetic Gastroparesis

Through rigorous clinical trials, the center is evaluating the efficacy of new drug formulations and treatment regimens, aiming to provide relief and better management of these chronic conditions.

Neurology and Sleep Disorders

The center is also making strides in neurology and the treatment of sleep disorders, with a particular focus on insomnia. Research is aimed at comparing pharmacological treatments with cognitive behavioral therapy to improve sleep quality.

  • Insomnia

By exploring the efficacy of various treatment modalities, the center is contributing to the development of more effective and personalized approaches to managing sleep disorders.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Site location
Willy Brandtlaan 106716 RP EdeThe Netherlands
Recruiting now
23 trials
Conditions studied
56

More sites in EdeThe Netherlands

Recruiting now

Ongoing trials

Clinical trials currently enrolling participants at this site.

Condition
Type of trial
Recruitment status
Quick filters

56 clinical trials

Phase III Randomized Study of Rilvegostomig vs. Pembrolizumab with Platinum-based Chemotherapy in PD-L1 Expressing Metastatic Squamous NSCLC

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:AstraZeneca AB

Study of Zilebesiran Added to Standard Treatment to Reduce Heart Problems in Adults with High Blood Pressure and Heart Disease Risk

Investigational
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Zilebesiran
  • Sponsor:Alnylam Pharmaceuticals Inc.
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Baxdrostat
  • Sponsor:AstraZeneca AB

Study comparing rilvegostomig plus chemotherapy versus pembrolizumab plus chemotherapy for first-line treatment in patients with metastatic non-squamous lung cancer with PD-L1 expression

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:AstraZeneca AB

Study on Selatogrel for Preventing Heart Attack in Patients with Recent Heart Attack History

Investigational
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Selatogrel
  • Sponsor:Viatris Innovation GmbH

Phase 2 study of MK-7262 and enlicitide decanoate in adults with high lipoprotein(a)

Investigational
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Sponsor:Merck Sharp & Dohme LLC

Rituximab and venetoclax treatment for 6 vs 26 cycles in patients with relapsed or refractory chronic lymphocytic leukemia

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Venetoclax
  • Sponsor:Haemato Oncology Foundation For Adults Netherlands

Cardiac failure+1

Recruiting

Study of Zenagamtide (NNC0487-0111) versus placebo in patients with heart failure with preserved or mildly reduced ejection fraction and obesity

Investigational
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:POLYPEPTIDE CONSISTING OF A GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONIST AND AN AMYLIN RECEPTOR AGONIST, CONNECTED BY A LINKER WITH 4 GLYCINE RESIDUES, AND CONNECTED TO A C18 FATTY ACID SIDE CHAIN
  • Sponsor:Novo Nordisk A/S

Study of pembrolizumab, capecitabine, or olaparib in patients with early-stage triple negative breast cancer and remaining disease after initial treatment

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Capecitabine
  • Sponsor:Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting

Study on Letrozole and Gonadotropins for Women with Polycystic Ovary Syndrome (PCOS) to Improve Live Birth Rates

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years
  • Substances:Follitropin Alfa
  • Sponsor:Amsterdam UMC Stichting

Study on Venetoclax, Obinutuzumab, and Pirtobrutinib for Patients with Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Obinutuzumab
  • Sponsor:University Of Cologne

Rectal cancer

Recruiting

Study Comparing Surgery and Chemoradiotherapy with Capecitabine for Early Rectal Cancer Patients

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Capecitabine
  • Sponsor:Amsterdam UMC Stichting
Is this your site?

Join our network of research sites

Get verified: confirm your contact details and recruitment status with us, appear first on the pages of your trials and receive patient requests directly.

See the offer for sites
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.